Answers are grounded in this paper and cite their sources.
Objective: To describe the relationship between advanced glycation and the development of cardiovascular diseases in patients with type 2 Diabetes Mellitus (T2DM), emphasizing pathophysiological mechanisms, biomarkers, assessment methods, and prevention and treatment strategies. Methods: This is an integrative literature review conducted using the MEDLINE/PubMed, LILACS, SciELO, Embase, and Scopus databases. Studies published preferably between 2020 and 2025 in Portuguese, English, or Spanish were included. Study selection was performed independently by two reviewers, followed by a descriptive analysis of the evidence. Results/Discussion: The evidence demonstrates that advanced glycation end products (AGEs) promote inflammation, oxidative stress, endothelial dysfunction, and vascular remodeling, primarily through activation of the AGE–RAGE axis, thereby contributing to atherosclerosis and increasing cardiovascular risk. Biomarkers such as Nε-carboxymethyl lysine (CML), methylglyoxal-derived hydroimidazolone-1 (MG-H1), soluble receptor for advanced glycation end products (sRAGE), the hemoglobin glycation index (HGI), and skin autofluorescence have shown potential for cardiovascular risk stratification. However, their clinical application remains limited by the lack of standardized assessment methods and the predominance of observational studies. Final considerations: Advanced glycation is an important mechanism associated with increased cardiovascular risk in patients with T2DM. However, prospective studies and standardized protocols are still needed to validate the clinical application of these biomarkers and to expand their use in the prevention and management of cardiovascular complications.
No takes yet. Share an insight, caveat, or question.
Machado et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: